Supervisory Medical Officer
US Food and Drug Administration
Amy Rosenberg received her MD from Albert Einstein College of Medicine and is Board Certified in Internal Medicine. She was a post-doctoral fellow in Al Singer’s Laboratory in the NCI before coming to CBER, FDA. She became Director of the Division of Therapeutic Proteins, CBER/CDER in 2000 (now DBRR3 in the Office of Biotechnology Products, CDER) which regulates diverse protein therapeutics, including monoclonal antibodies and fusion proteins, enzyme replacement therapies, hematologic and somatic cell growth factors, and immunomodulatory agents. She has been a driving force in risk evaluation and mitigation pertaining to the immunogenicity of therapeutic proteins (Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products 2014) and in the elucidation and implementation of immune tolerance induction protocols in clinical settings. She co-edited the AAPS/Springer Book “Biobetters: Protein Engineering to Approach the Curative”.